Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02734277 · ClinicalTrials.gov registry record
Type 1 Diabetes Extension Study
A clinical trial of Type 1 Diabetes Mellitus and T1D, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- 111
- Enrollment target
- 12
- Study locations
NCT02734277: Recruiting study of Type 1 Diabetes Mellitus and T1D, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT02734277 is a study of Type 1 Diabetes Mellitus and T1D that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 111 participants, below the 171-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (35% lower). The trial reports 12 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02734277, a study of Type 1 Diabetes Mellitus and T1D, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- 111 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D). This observational study will: * follow participants to determine how long they continue to produce insulin, and * will also assess how changes in the immune system over time relate to the ability to produce insulin. This information could help design better therapies for type 1 diabetes in the future.
Primary Outcome
Evaluation of changes in beta cell function over time will be measured by mixed-meal tolerance test (MMTT) -Stimulated mean C-Peptide area under the curve (AUC). C-peptide is released by the pancreas into the bloodstream in equal amounts to insulin and reflects how much insulin pancreatic beta cells are making. The standardized MMTT evaluates whether beta cells are producing endogenous insulin. Detectable C-peptide is defined as any value during a MMTT of ≥0.15 ng/mL.
Conditions Studied
Study Locations (12)
California
- UCSF School of Medicine - San Francisco
- Stanford University - Stanford
Colorado
- University of Colorado School of Medicine: Barbara Davis Center for Diabetes - Aurora
Connecticut
- Yale University - New Haven
Georgia
- Emory University - Atlanta
Indiana
- Indiana University Riley Hospital for Children - Indianapolis
Iowa
- University of Iowa Health Care Division of Pediatric Endocrinology - Iowa City
Massachusetts
- Joslin Diabetes Center - Boston
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2016-08-18 |
| Est. Completion | 2028-08 |
What NCT02734277 shows while recruiting
NCT02734277 is an observational study that tracks outcomes without assigning an intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, below the 171-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (35% lower).
The record links to 3 conditions, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 0 interventions.
NCT02734277 lists 12 locations in 11 states (California, Colorado, Connecticut).
Frequently Asked Questions
What is clinical trial NCT02734277 about?
NCT02734277 is a clinical study titled "Type 1 Diabetes Extension Study". This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D). This observational study will: * follow participants to determine how lon...
What is the current status of trial NCT02734277?
This trial is currently recruiting. The enrollment target is 111 participants. The study started on 2016-08-18. Estimated completion is 2028-08.
What conditions does trial NCT02734277 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus, T1D, T1DM.
Who is sponsoring clinical trial NCT02734277?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02734277 being conducted?
This trial has 12 study locations across California, Colorado, Connecticut, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02734277's enrollment target sits among peer trials
111 32nd of 112 higher than 81 of 112 other Type 1 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
RECRUITING · Phase 2
-
Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes
RECRUITING · Phase 1
-
Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)
RECRUITING · Phase 1
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
Dapagliflozin Plus Pioglitazone in T1DM
RECRUITING · Phase 4
-
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03875716 · 111 participants · NA
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- NCT04693468 · 111 participants · Phase 1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- NCT05263050 · 111 participants · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- NCT05600842 · 111 participants
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI